Home > Healthcare > Biotechnology > Bioservices > Spatial Genomics and Transcriptomics Market
Spatial Genomics and Transcriptomics Market size was estimated at USD 305.7 million in 2022 and is projected to increase at a CAGR of 15.2% from 2023 to 2032. The market is driven by the various factors such as increasing demand for new technologies that can be used to study the spatial organization genome, increasing research focus on spatial biology, growing demand for deeper insights into cellular function and organization, and advances in sequencing technologies.
Spatial genomics and transcriptomics allow for the integration of multi-omics data, including genomics, transcriptomics, proteomics, and epigenomics. By combining different layers of molecular information with spatial context, researchers can gain a more comprehensive understanding of biological processes and cellular interactions. The demand for integrated multi-omics approaches has contributed to the market growth.
Report Attribute | Details |
---|---|
Base Year: | 2022 |
Spatial Genomics and Transcriptomics Market Size in 2022: | USD 305.7 Million |
Forecast Period: | 2023 to 2032 |
Forecast Period 2023 to 2032 CAGR: | 15.2% |
2032 Value Projection: | USD 1.2 Billion |
Historical Data for: | 2018 to 2022 |
No. of Pages: | 364 |
Tables, Charts & Figures: | 620 |
Segments covered: | Technique, Product, Application, End-user, and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
The COVID-19 epidemic has impacted workflows in the healthcare industry all across the globe. The disease has compelled a number of companies, including various sub-domains of health care, to temporarily close their doors. The global spatial genomics and transcriptomics market declined in 2020 as a result of the global economic slowdown caused by COVID-19. Furthermore, the COVID-19 epidemic impacted the supply chain in a variety of end-user industries including academic and research, pharmaceutical and biotechnology, and others.
Moreover, the pandemic's impact and decreasing global research activities have also had a negative impact on the operations and economic growth of several market players. The closure of academic and research institutes has resulted in a decrease in sales of consumables and reagents used in spatial genomics and transcriptomics analyses. However, the market is recovering from 2021 owing to an increase in the application of spatial genomics and transcriptomics to analyse COVID-19 tissue autopsy, as well as an increase in biomarker identification and usage in drug research and development programmes.
The market is experiencing several key trends that are shaping its development and driving innovation. Some of the prominent trends in the field include integration of spatial and single-cell technologies, advancements in imaging technologies, emergence of in-situ sequencing techniques, and increasing adoption of machine learning and computational analysis. These key trends are driving advancements and innovation in the market, leading to the development of more powerful and sophisticated tools and applications.
Based on technique, the spatial genomics and transcriptomics market is segmented as spatial transcriptomics and spatial genomics analysis. The spatial transcriptomics segment further divided into immunohistochemistry (IHC), fluorescent in-situ hybridization (FISH), sequencing, in-situ capturing, in-silico construction, microscopy-based RNA imaging techniques, and transcriptome in-vivo analysis (TIVA). In 2022, the spatial transcriptomics segment accounted for the majority of the market size and is expected to grow at the fastest rate throughout the forecast period. Owing to uncovering spatially resolved gene expression, integration of spatial and single-cell analysis, applications in disease research and drug discovery, and technological advancements in spatial analysis methods.
Based on product, the spatial genomics and transcriptomics market is segmented as consumables, instruments, and software. The in consumables held a dominant market share of around 54% in 2022 and is expected to grow at a significant pace during the analysis period. The growing adoption of spatial genomics and transcriptomics technologies in research and clinical settings is a significant driver for consumables. As more researchers and laboratories integrate spatial analysis into their studies, there is a corresponding increase in the demand for consumable products required to perform these experiments.
Based on application, the spatial genomics and transcriptomics market is segmented as translational research, and drug discovery & development. The translational research segment held a dominant market share in 2022 and is expected to grow at a significant pace of 18.3% between 2023 to 2032. Translational research aims to bridge the gap between basic research discoveries and their practical applications in clinical settings. The potential clinical relevance and utility of spatial genomics and transcriptomics technologies drive the need for translational research.
By translating scientific knowledge into actionable insights, researchers and clinicians can develop new diagnostic tools, therapeutic targets, and precision medicine approaches based on spatial genomic and transcriptomic information. This collectively contribute to the importance and growth of translational research in the market.
Based on end user, the spatial genomics and transcriptomics market is segmented as pharmaceutical & biotechnology companies, contract research organizations, and academic & research institutes. The pharmaceutical & biotechnology companies segment held a dominant market share in 2022 and is expected to grow at a significant pace between 2023 to 2032. Factors include increasing demand for precision medicine, advancement of targeted therapies, and enhancing preclinical and clinical research. Spatial genomics and transcriptomics technologies offer new avenues for exploring disease biology and validating therapeutic interventions.
By integrating spatial information with genomic and transcriptomic data, pharmaceutical and biotechnology companies can gain a more comprehensive understanding of disease mechanisms, assess drug efficacy, and evaluate treatment responses. This enables more informed decision-making in preclinical and clinical research, increasing the chances of success in drug development. This is expected to drive the segment growth in the market.
North America spatial genomics and transcriptomics market accounted for significant revenue in 2022 and is anticipated to grow at 15.3% during the forecast timeframe. North America has a robust research and development landscape, with a high concentration of pharmaceutical and biotechnology companies, academic institutions, and research organizations. These entities actively engage in cutting-edge genomics and transcriptomics research. The region's emphasis on innovation, investment in research, and collaboration between academia and industry drives the regional market expansion.
Moreover, North America is at the forefront of precision medicine initiatives. Spatial genomics and transcriptomics technologies offer valuable insights into the spatial organization of genes and cells, enabling personalized and targeted therapies. The focus on precision medicine in North America drives the demand for spatial genomics and transcriptomics technologies, as researchers and healthcare providers seek to integrate spatial information into patient care, leading to market progress.
Some of the major market players operating in the spatial genomics and transcriptomics market are :
The spatial genomics and transcriptomics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032, for the following segments: Click here to Buy Section of this Report
By Spatial transcriptomics, 2018 - 2032 (USD Million)
By Product, 2018 - 2032 (USD Million)
By Application, 2018 - 2032 (USD Million)
By End-user, 2018 - 2032 (USD Million)
The above information is provided for the following regions and countries: